Stephen B. Kay Family Professor of Medicine, Dana-Farber Cancer Institute
Internal Medicine
Dr. Robert G. Mayer, MD
|
|
Give Review
Robert Mayer works in the field of Internal Medicine. He studied medicine at Harvard Medical School. Harvard Medical School is a top medical university. Harvard Medical School is ranked 1 in research and 12 in primary care medicine He has 2 awards "Fellow (FASCO)" and "Super Doctor". Robert Mayer is a published doctor and has 84 publications published. The lastest was: 'Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation.'
Publications
- Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation.
- Aspirin and COX-2 inhibitor use in patients with stage III colon cancer.
- Anal Carcinoma: Impact of TN Category of Disease on Survival, Disease Relapse, and Colostomy Failure in US Gastrointestinal Intergroup RTOG 98-11 Phase 3 Trial.
- Association of TP53 Mutational Status and Gender with Survival After Adjuvant Treatment for Stage III Colon Cancer: Results of CALGB 89803.
- Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors.
- Clinical practice guidelines for cancer care: utilization and expectations of the practicing oncologist.
- Perspective: A Culture of Respect, Part 2: Creating a Culture of Respect.
- Perspective: A Culture of Respect, Part 1: The Nature and Causes of Disrespectful Behavior by Physicians.
- Locally advanced anaplastic pancreatic adenocarcinoma with initial response to FOLFIRINOX and rapid progression after five months.
- Predictive and Prognostic Roles of BRAF Mutation in Stage III Colon Cancer: Results from Intergroup Trial CALGB 89803.
- Relationship Between Statin Use and Colon Cancer Recurrence and Survival: Results From CALGB 89803.
- Documenting the Natural History of Patients With Resected Stage II Adenocarcinoma of the Colon After Random Assignment to Adjuvant Treatment With Edrecolomab or Observ...
- Microsatellite Instability and Loss of Heterozygosity at Chromosomal Location 18q: Prospective Evaluation of Biomarkers for Stages II and III Colon Cancer--A Study of ...
- Multivitamin use is not associated with cancer recurrence or survival in patients with stage III colon cancer: findings from CALGB 89803.
- Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11).
- Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CA...
- By the way, doctor. I read that President Obama had a virtual colonoscopy. Is this the colon cancer screening test that everybody should be getting instead of a regu...
- A step forward in the treatment of advanced biliary tract cancer.
- The American Society of Clinical Oncology Cancer Foundation Grants Program: a 25-year report and a look toward the future.
- Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancr...
- By the way, doctor. We have screening tests for other cancers. How about pancreatic cancer?
- Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia ...
- A compendium of potential biomarkers of pancreatic cancer.
- p27Kip1 in stage III colon cancer: implications for outcome following adjuvant chemotherapy in cancer and leukemia group B protocol 89803.
- Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer.
- US intergroup anal carcinoma trial: tumor diameter predicts for colostomy.
- Targeted therapy for advanced colorectal cancer--more is not always better.
- Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study.
- Induction therapy for poor-prognosis anal canal carcinoma: a phase II study of the cancer and Leukemia Group B (CALGB 9281).
- Association of family history with cancer recurrence and survival among patients with stage III colon cancer.
- Systemic treatment of colorectal cancer.
- By the way, doctor. Cancer of the small intestine.
- Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial.
- A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer...
- Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer?
- Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer.
- Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803.
- Adjuvant treatment of colorectal cancer.
- The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer.
- Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
- Systemic treatment of patients who have colorectal cancer and inflammatory bowel disease.
- Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803.
- Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144.
- Cancer and leukemia group B gastrointestinal cancer committee.
- Fifty years of clinical research by the leukemia committee of the cancer and leukemia group B.
- Colorectal Cancer Screening Clinical Practice Guidelines.
- Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers...
- Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089.
- Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes.
- A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma.
- Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Gr...
- Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levami...
- Systemic therapy for colorectal cancer.
- Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.
- Epigenetic inactivation of RUNX3 in microsatellite unstable sporadic colon cancers.
- APC promoter hypermethylation contributes to the loss of APC expression in colorectal cancers with allelic loss on 5q.
- Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors.
- Two steps forward in the treatment of colorectal cancer.
- Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis.
- Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers.
- Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.
- Gastrointestinal cancer in older patients.
- Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461.
- Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114.
- Impact of hospital procedure volume on surgical operation and long-term outcomes in high-risk curatively resected rectal cancer: findings from the Intergroup 0114 Study.
- Evaluation of microsatellite instability, hMLH1 expression and hMLH1 promoter hypermethylation in defining the MSI phenotype of colorectal cancer.
- A phase II study of docetaxel in patients with metastatic carcinoid tumors.
- Esophageal cancer.
- Association of hospital procedure volume and outcomes in patients with colon cancer at high risk for recurrence.
- Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma.
- Follow-up strategies after curative resection of colorectal cancer.
- Characterization of sporadic colon cancer by patterns of genomic instability.
- Accuracy of determining nodal negativity in colorectal cancer on the basis of the number of nodes retrieved on resection.
- Impact of diabetes mellitus on outcomes in patients with colon cancer.
- A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancer.
- Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas.
- Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: a pooled analysis.
- Acute diarrhea during adjuvant therapy for rectal cancer: a detailed analysis from a randomized intergroup trial.
- A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer.
- Outcomes and toxicity in african-american and caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer.
- A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma.
- Surveillance for second primary colorectal cancer after adjuvant chemotherapy: an analysis of Intergroup 0089.
- A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma.
Schools
Thomas Jefferson University
Pa Hospital
Tufts New Eng Med Center
Doctors Specialties
- Psychiatry
- Internal Medicine
Accepted Insurances
Awards
- Fellow (FASCO)
- Super Doctor
Education
-
Mount Sinai School of Medicine -
Harvard Medical School
Hospital
-
Massachusetts General Hospital -
Dana-Farber Cancer Institute -
Brigham and Women's Hospital
Drug Facts
| NPI NUMBER | 1659361327 | |
| NPPES Provider LastName | MAYER | |
| NPPES Provider FirstName | ROBERT | |
| NPPES Provider ZIPCode | 022155418 | |
| NPPES Provider State | MA | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 101.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1659361327 |
| Last Name Of The Provider | MAYER |
| First Name Of The Provider | ROBERT |
| View All |
Similar Doctors
|
|
Dr. Richard A. Serrao, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Laura A. Bajor, DO |
|
|
Dr. Steve D. Stelovich, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paul M. Schoenfeld, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Landis A. Mitchner, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James D. Laudate, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Elizabeth Loder, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John Jewett, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Maria Copello, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniella Floru, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Raman Mehrzad, MD |
|
|
Dr. Bevin E. Kenney, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Keelin F. Roche, MD
This Doctor is OpenDoctor Recommended.
|